IVA (Inventiva) Operating Margin %: -266,002.94% (As of Dec. 2025)


IVA Inventiva SA IVA
40 GF Score
Price $3.48
GF Value $0.29
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Operating Margin %?

Inventiva IVA -6.36% 40 Operating Margin % is -266,002.94% as of Dec. 2025. GuruFocus rates IVA with a GF Score™ of 40/100 and a GF Value™ of $0.29 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 945 Biotechnology companies, Inventiva ranks worse than 86.56% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Inventiva's Operating Income for the six months ended in Dec. 2025 was $-90.44 Mil. Inventiva's Revenue for the six months ended in Dec. 2025 was $0.03 Mil. Therefore, Inventiva's Operating Margin % for the quarter that ended in Dec. 2025 was -266,002.94%.

Good Sign:

Inventiva SA operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Inventiva's Operating Margin % or its related term are showing as below:

IVA' s Operating Margin % Range Over the Past 10 Years
Min: -7136.02   Med: -773.06   Max: -127.56
Current: -2964.15


IVA's Operating Margin % is ranked worse than
86.56% of 945 companies
in the Biotechnology industry
Industry Median: -86.77 vs IVA: -2964.15

Inventiva's 5-Year Average Operating Margin % Growth Rate was 12.60% per year.

Inventiva's Operating Income for the six months ended in Dec. 2025 was $-90.44 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $-154.62 Mil.

Warning Sign:

Inventiva SA has never been profitable in the past 3 years. It lost money every year.


Inventiva  (NAS:IVA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Inventiva Operating Margin % Related Terms


Inventiva Operating Margin % Historical Data

* Premium members only.

The historical data trend for Inventiva's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Operating Margin % Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,220.17 -466.86 -587.42 -1,021.89 -2,964.39

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -306.00 -128,161.36 -454.34 -1,249.41 -266,002.94

IVA vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Inventiva's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Inventiva's Operating Margin % falls into.


IVA
40GF Score
Inventiva SA IVA
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Inventiva's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-155.601 / 5.249
=-2,964.39 %

Inventiva's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-90.441 / 0.034
=-266,002.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -266,002.94% mean?
Inventiva (IVA) has a Operating Margin % of -266,002.94% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Inventiva and its competitors. According to the industry distribution chart, Inventiva ranks #818 out of 945 companies in the Biotechnology industry, placing it in the top 86.6%.
Is Inventiva's Operating Margin % too high?
Inventiva's current Operating Margin % is -266,002.94%. Based on the distribution chart, Inventiva ranks #818 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inventiva has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inventiva ranks #818 out of 945 companies for Operating Margin %. This places Inventiva in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Inventiva and its competitors. Inventiva's current Operating Margin % is -266,002.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (IVA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $3.48 — trading 1100% above its estimated fair value. The current Operating Margin % is -266,002.94%. Inventiva's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Inventiva (IVA), the current Operating Margin % is -266,002.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (IVA) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.48 is trading 1100% above its estimated GF Value™ of $0.29. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVA:

  • Operating Margin %: -266,002.94%
  • GF Value™: $0.29 vs. price of $3.48 (1100% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the IVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score

Get the complete analysis for IVA

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.48
Price
$0.29
GF Value